Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar;176(5):750-758.
doi: 10.1111/bjh.14477. Epub 2016 Dec 16.

The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma

Dai Chihara  1 , Michelle A Fanale  1 , Roberto N Miranda  2 , Mansoor Noorani  1 , Jason R Westin  1 , Loretta J Nastoupil  1 , Fredrick B Hagemeister  1 , Luis E Fayad  1 , Jorge E Romaguera  1 , Felipe Samaniego  1 , Francesco Turturro  1 , Hun J Lee  1 , Sattva S Neelapu  1 , M Alma Rodriguez  1 , Michael Wang  1 , Nathan H Fowler  1 , Richard E Davis  1 , L Jeffrey Medeiros  2 , Chitra Hosing  3 , Yago L Nieto  3 , Yasuhiro Oki  1
Affiliations

The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma

Dai Chihara et al. Br J Haematol. 2017 Mar.

Abstract

Survival outcome of patients with peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) and angioimmunoblastic T-cell lymphoma (AITL) who experience disease progression/relapse remains very poor. A total of 321 patients, newly diagnosed with PTCL-NOS (n = 180) or AITL (n = 141) between 1999 and 2015, were analysed. Failure-free survival (FFS) and overall survival (OS) were calculated from the time of first disease progression (FFS1, OS1), from second disease progression (FFS2, OS2) and from third progression (FFS3, OS3). With a median follow-up duration of 52 months, 240 patients (135 PTCL-NOS, 105 AITL) experienced progression/relapse. In patients with PTCL-NOS, the median durations of FFS1, FFS2 and FFS3 were 3·1, 2·5 and 2·1 months, respectively. In patients with AITL, they were 5·5, 2·9 and 2·3 months, respectively. There was no improvement in FFS1 and OS1 by the time of recurrence during this period (1999-2004, 2005-2009 and 2010-2015). The median FFS after pralatrexate and romidepsin was only 3·0 and 2·5 months, respectively. The 5-year OS rates after salvage autologous and allogeneic transplant were 32% and 52%, respectively; while the 5-year OS rates for patients who did not undergo transplant was 10%. Further research for novel therapeutic approaches with higher efficacy and better safety profile are needed.

Keywords: Peripheral T-cell lymphoma; pralatrexate; relapse/refractory; romidepsin.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest Disclosure:

Yasuhiro Oki

Honoraria: Takeda Millenium

Research funding: Seattle Genetics, Takeda Millenium and Spectrum

Michelle Fanale

Honoraria: Celgene, Spectrum

Research funding: Celgene, Seattle Genetics

Consulting or Advisory Role: Celgene, Spectrum

Nathan Fowler

Research funding: Celgene

Consulting or Advisory Role: Celgene

Jorge Romaguera

Research funding: Celgene

Chitra Hosing

Research funding: Celgene

Figures

Figure 1
Figure 1
A, Failure-free survival by the time of progression/relapse; B, Overall survival by the time of progression/relapse
Figure 2
Figure 2. A, Failure-free survival after first, second and third progression/relapse for PTCL-NOS; B, Overall survival after first, second and third progression/relapse for PTCL-NOS; C, Failure-free survival after first, second and third progression/relapse for AITL; D, Overall survival after first, second and third progression/relapse for AITL
AITL, angioimmunoblastic T-cell lymphoma; FFS, failure-free survival; OS, overall survival; PTCL-NOS, peripheral T-cell lymphoma-not otherwise specified.
Figure 3
Figure 3
A, Overall survival after autologous stem cell transplant (auto-SCT); B, Overall survival after allogeneic stem cell transplant (allo-SCT); C, Overall survival after relapse without transplant
See this image and copyright information in PMC

References

    1. Cabanillas F, Rodriguez-Diaz Pavon J, Hagemeister FB, McLaughlin P, Rodriguez MA, Romaguera JE, Dong K, Moon T. Alternating triple therapy for the treatment of intermediate grade and immunoblastic lymphoma. Ann Oncol. 1998;9:511–518. - PubMed
    1. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244. - PubMed
    1. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V International Harmonization Project on L. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–586. - PubMed
    1. Chihara D, Ito H, Matsuda T, Shibata A, Katsumi A, Nakamura S, Tomotaka S, Morton LM, Weisenburger DD, Matsuo K. Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol. 2014;164:536–545. - PMC - PubMed
    1. Chihara D, Pro B, Loghavi S, Miranda RN, Medeiros LJ, Fanale MA, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Neelapu SS, Younes A, Fowler NH, Rodriguez MA, Wang M, Kwak LW, McLaughlin P, Dang NH, Oki Y. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol. 2015;171:509–516. - PubMed

Publication types

MeSH terms

LinkOut - more resources